{"commentary":{"count":81,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":33,"podcast":29,"youtube":19},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03138512\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"CheckMate 914","nct_id":"NCT03138512","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=checkmate-914-nct03138512. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"CheckMate 914","arms":[{"description":null,"label":"Part A, Arm A: nivolumab + ipilimumab","type":"EXPERIMENTAL"},{"description":null,"label":"Part A, Arm B: nivolumab placebo + ipilimumab placebo","type":"PLACEBO_COMPARATOR"},{"description":null,"label":"Part B, Arm A: nivolumab + ipilimumab","type":"EXPERIMENTAL"},{"description":null,"label":"Part B, Arm B: nivolumab placebo + ipilimumab placebo","type":"PLACEBO_COMPARATOR"},{"description":null,"label":"Part B, Arm C: nivolumab + ipilimumab placebo","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2024-02-01","type":"ACTUAL"},"conditions":["Carcinoma, Renal Cell"],"enrollment":{"count":1641,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"nivolumab","type":"BIOLOGICAL"},{"name":"ipilimumab","type":"BIOLOGICAL"},{"name":"nivolumab placebo","type":"DRUG"},{"name":"ipilimumab placebo","type":"DRUG"}],"last_update":"2024-12-18","lead_sponsor":"Bristol-Myers Squibb","official_title":"A Phase 3 Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab vs Placebo in Participants With Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2023-09-28","type":"ACTUAL"},"primary_outcomes":[{"measure":"Disease-Free Survival (DFS) by BICR - Treatment Part A and B","timeFrame":"From randomization to development of local disease recurrence, distance metastasis, or death, whichever came first (up to approximately 72 months)"}],"references":[{"citation":"Motzer RJ, Bex A, Russo P, Tomita Y, Cutuli HJ, Rojas C, Gross-Goupil M, Schinzari G, Melichar B, Barthelemy P, Ruiz Garcia A, Sosman J, Grimm MO, Goh JC, Suarez C, Kollmannsberger CK, Nair SG, Shuch BM, Huang J, Simsek B, Spiridigliozzi J, Lee CW, van Kooten Losio M, Grunwald V. Adjuvant Nivolumab for Localized Renal Cell Carcinoma at High Risk of Recurrence After Nephrectomy: Part B of the Randomized, Placebo-Controlled, Phase III CheckMate 914 Trial. J Clin Oncol. 2025 Jan 10;43(2):189-200. doi: 10.1200/JCO.24.00773. Epub 2024 Sep 20.","pmid":"39303200","type":"DERIVED"},{"citation":"Motzer RJ, Russo P, Grunwald V, Tomita Y, Zurawski B, Parikh O, Buti S, Barthelemy P, Goh JC, Ye D, Lingua A, Lattouf JB, Albiges L, George S, Shuch B, Sosman J, Staehler M, Vazquez Estevez S, Simsek B, Spiridigliozzi J, Chudnovsky A, Bex A. Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial. Lancet. 2023 Mar 11;401(10379):821-832. doi: 10.1016/S0140-6736(22)02574-0. Epub 2023 Feb 9.","pmid":"36774933","type":"DERIVED"},{"citation":"Marconi L, Sun M, Beisland C, Klatte T, Ljungberg B, Stewart GD, Dabestani S, Choueiri TK, Bex A. Prevalence, Disease-free, and Overall Survival of Contemporary Patients With Renal Cell Carcinoma Eligible for Adjuvant Checkpoint Inhibitor Trials. Clin Genitourin Cancer. 2021 Apr;19(2):e92-e99. doi: 10.1016/j.clgc.2020.12.005. Epub 2021 Jan 7.","pmid":"33526329","type":"DERIVED"}],"start_date":{"date":"2017-07-07","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney","url":"https://clinicaltrials.gov/study/NCT03138512"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/checkmate-914-nct03138512"}